Adalta

Adalta Forward P/E

The Forward P/E Ratio of Adalta (1AD.AX) as of Oct 20, 2026 is -1.91. In the previous year, Forward P/E Ratio was -1.98 — a change of -3.88% (higher).

Forward P/E

-1.91

YoY

-3.88%

Last updated:

Forward P/E Ratio of Adalta is 2026 -1.91 . Forward P/E Ratio of Adalta was 2025 -1.98 . It decreases by -3.88% higher compared to the previous year.

The Adalta Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
-1.51 AUD
Jan 1, 2020
-1.49 AUD
Jan 1, 2021
-1.59 AUD
Jan 1, 2022
-1.47 AUD
Jan 1, 2023
-1.84 AUD
Jan 1, 2024
-1.66 AUD
Jan 1, 2025
-1.98 AUD
Jan 1, 2026
-1.91 AUD
The Adalta Forward P/E history
YEARForward P/EYoY
-1.91-3.88%
-1.98+19.52%
-1.66-9.85%
-1.84+24.94%
-1.47-7.14%
-1.59+6.72%
-1.49-1.47%
-1.51-34.86%
-2.31-26.52%
-3.15-58.94%
-7.67+12.45%
-6.82-4.51%
-7.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adalta Stock analysis

What does Adalta do? AdAlta Ltd. operates as a biotechnology company that discovers, develops, and commercializes protein based therapeutics. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies. Adalta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adalta stock

Forward P/E Ratio of Adalta is -1.91 in 2026.

Forward P/E Ratio of Adalta changed from -1.98 to -1.91, representing a -3.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Adalta since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Adalta with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Adalta

All Key Metrics — Adalta